Last reviewed · How we verify
test SHR3680 tablets — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
test SHR3680 tablets (test SHR3680 tablets) — Jiangsu HengRui Medicine Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| test SHR3680 tablets TARGET | test SHR3680 tablets | Jiangsu HengRui Medicine Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- test SHR3680 tablets CI watch — RSS
- test SHR3680 tablets CI watch — Atom
- test SHR3680 tablets CI watch — JSON
- test SHR3680 tablets alone — RSS
Cite this brief
Drug Landscape (2026). test SHR3680 tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/test-shr3680-tablets. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab